Abstract:Purpose/objectives: Diethylhexylphthalate (DEHP) is a lipid-soluble plasticizer commonly used in the manufacture of polyvinyl chloride- (PVC-) based plastics. Previous studies have documented the leaching of DEHP from PVC-based containers and extension sets during the IV administration of paclitaxel. Design: Study of the leaching of DEHP from infusion bags and peritoneal dialysis solution transfer sets and clinical study of DEHP was proposed. Setting: The experiments were performed in a laboratory with plastic ware normally used for intraperitoneal chemotherapy delivery. Sample: Samples were taken from fluids that had been in contact with the plastic ware. Also, blood, peritoneal fluid, and urine were collected from a patient. Methods: In a controlled laboratory environment, the authors used an established high-performance liquid chromatography assay to determine the rate and extent of DEHP leaching from infusion bags and in the solution transfer set used for early postoperative intraperitoneal chemotherapy (EPIC) administration of paclitaxel. Paclitaxel was tested at a concentration of 40 mg/L to simulate the median dose used for EPIC. In a single patient receiving 34 mg paclitaxel in 1 liter of 1.5% dextrose peritoneal dialysis solution (Dianeal), the presence and concentration of DEHP in samples of peritoneal fluid and urine were determined during the first 24-hour EPIC administration. Main research variables: DEHP levels in fluids exposed to plastic ware and in the patients blood, peritoneal fluid, and urine were determined. Findings: The in vitro studies showed that a solution of 40 mg paclitaxel dissolved in a 1 liter bag of Dianeal resulted in the extraction of approximately 26 mg DEHP over 24 hours. Approximately 2 mg DEHP was leached during the first hour and approximately 1 mg per hour over the following 23 hours. Equivalent results were obtained when 20 mg paclitaxel was dissolved in a 500 ml bag of 6% hetastarch (Hespan) with a leaching of approximately 13 mg DEHP in 24 hours. Using the same paclitaxel concentration, the chronic ambulatory peritoneal dialysis solution transfer tubing with a total capacity of 10 ml produced approximately 2 mg DEHP over 24 hours, of which approximately 0.5 mg was produced during the first four hours. Samples from a single patient showed that immediately prior to administration, a 1 liter bag of Dianeal containing 34 mg paclitaxel had about 3.3 mg DEHP. Approximately 3% (110 mcg) of unchanged DEHP was recovered from the peritoneal fluid at 24 hours. Total DEHP excreted in urine over the 24-hour period was approximately 900 mcg (27%). Conclusion: This study showed that the carcinogen DEHP is leached after preparation of paclitaxel from PVC-based containers and DEHP constantly accumulates in the solution transfer tubing. Implications for nursing: Unless precautionary steps are taken, DEHP can be transferred to patients receiving intraperitoneal paclitaxel. Steps to minimize patient exposure to DEHP during EPIC with paclitaxel are necessary. In the ideal situation, no DEHP-containing plastic should be used for chemotherapy delivery. If that is not possible, (a) paclitaxel solution should be administered as soon as possible after preparation by the pharmacy, (b) infusion should proceed as rapidly as possible via the Tenckhoff catheter, and (c) the Tenckhoff catheter and extension tubing should be cleared by draining ascites fluid through these tubes prior to subsequent intraperitoneal infusions.

Compatibility of Paclitaxel Injection Diluent with Two Reduced-Phthalate Administration Sets for the Acclaim Pump.

The extraction of diethylhexylphthalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection

Avoiding carcinogen exposure with intraperitoneal paclitaxel

Quantification of paclitaxel in rat plasma by LC-MS/MS and pharmacokinetics of paclitaxel thermosensi-tive liposomes in rats

Physicochemical Stability of Nab-Paclitaxel (Pazenir) Infusion Dispersions in Original Glass Vials and EVA Infusion Bags

Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.

An Alternative Paclitaxel Self-Emulsifying Microemulsion Formulation: Preparation, Pharmacokinetic Profile, and Hypersensitivity Evaluation.

An alternative paclitaxel self-emulsifying microemulsion formulation: Preparation, pharmacokinetic profile, and evaluation

Preliminary in vivo studies of a new lecithin-based formulation of paclitaxel

Release of paclitaxel from polylactide-co-glycolide (PLGA) microparticles and discs under irradiation

Dddt_a_200679 1739..1749

Assessing outcomes of tapering 12-hr and 6-hr dexamethasone prior to paclitaxel infusions in patients with breast cancer

Preparation of pactilaxel for injection and its hypersusceptibility test

Phospholipid-Tween 80 mixed micelles as an intravenous delivery carrier for paclitaxel.

ANovel Paclitaxel Microemulsion Containing a Reduced Amount of Cremophor EL : Pharmacokinetics , Biodistribution , and InVivo Antitumor Efficacy and Safety

Development of copolymers of poly(d,l-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel

Stability study of docetaxel solution (0.9%, saline) using Non-PVC and PVC tubes for intravenous administration

Bioequivalence of Paclitaxel Protein-Bound Particles in Patients with Breast Cancer: Determining Total and Unbound Paclitaxel in Plasma by Rapid Equilibrium Dialysis and Liquid Chromatography–tandem Mass Spectrometry

[Studies on Hypersensitivity and Pharmacokinetics of Paclitaxel Microemulsion].

An NMR Protocol for In Vitro Paclitaxel Release from an Albumin-Bound Nanoparticle Formulation

Clinical Pharmacokinetics of Paclitaxel Liposome with a New Route of Administration in Human Based on the Analysis with Ultra Performance Liquid Chromatography